Elevated Interferon-induced Protein with Tetratricopeptide Repeats 3 (IFIT3) is a Poor Prognostic Marker in Pancreatic Ductal Adenocarcinoma

Overview

Journal J Cancer Res Clin Oncol

Specialty Oncology

Date 2017 Feb 18

PMID 28210844

Citations 18

Authors

Yue Zhao

Annelore Altendorf-Hofmann

Ioannis Pozios

Peter Camaj

Therese Daberitz

Xiaoyan Wang

Hanno Niess

Hendrik Seeliger

Felix Popp

Christopher Betzler

Utz Settmacher

Karl-Walter Jauch

Christiane Bruns

Thomas Knosel

Affiliations

Soon will be listed here.

Abstract

Purpose: Interferon-induced protein with tetratricopeptide repeats 3 (IFIT3) gene from IFITs family is one gene among hundreds of IFN-stimulated genes. The potential role of IFIT3 in cancer is scarcely understood. In addition, the clinical relevance of IFIT3 is not yet known in pancreatic ductal adenocarcinoma (PDAC). We evaluated the prognostic significance of this gene in PDAC patients.

Methods: The expression of IFIT3 was analyzed in pancreatic cancer cell lines with different metastatic potential (FG and L3.6pl) and one established gemcitabine resistant cell variant-L3.6plGres. Second, we analyzed the protein expression in tissue microarrays (TMA) from specimens of 254 radically resected patients with pancreatic adenocarcinoma. The prognostic relevance of IFIT3 was evaluated by the Kaplan-Meier and Cox regression analysis.

Results: L3.6pl cells with an aggressive capacity showed a significant higher expression of IFIT3 as compared to FG cells. IFIT3 was accumulated in gemcitabine resistant cells. Overexpression of IFIT3 increased the resistance of apoptosis against gemcitabine treatment. Patients who had high expression of IFIT3 (32%) and received chemotherapy had a statistically significant reduced survival in multivariate analysis.

Conclusions: High expression of IFIT3 enhances anti-apoptotic activity and chemotherapy resistance of PDAC cells. High expression of IFIT3 was independently correlated to shorter patients' survival and may serve as a prognostic marker.

Citing Articles

IFIT3: a crucial mediator in innate immunity and tumor progression with therapeutic implications.

Wu R, Yang H, Liu C Front Immunol. 2025; 16:1515718.

PMID: 40061935 PMC: 11885914. DOI: 10.3389/fimmu.2025.1515718.

HSP and CD279 gene expression as candidate biomarkers in symptomatic LGLL patients.

Talarico G, Franceschini A, Raveane A, Falvo P, Mazzara S, Melle F Discov Oncol. 2024; 15(1):764.

PMID: 39692827 PMC: 11655943. DOI: 10.1007/s12672-024-01657-y.

Genes involved in metastasis in oral squamous cell carcinoma: A systematic review.

Mohtasham N, Zarepoor M, Shooshtari Z, Hesari K, Mohajertehran F Health Sci Rep. 2024; 7(4):e1977.

PMID: 38665153 PMC: 11043498. DOI: 10.1002/hsr2.1977.

IFIT1 modulates the proliferation, migration and invasion of pancreatic cancer cells via Wnt/β-catenin signaling.

Li T, Zhao B, Qin C, Wang Y, Li Z, Cao H Cell Oncol (Dordr). 2024; 47(4):1253-1265.

PMID: 38536650 DOI: 10.1007/s13402-024-00925-x.

IFIT3 accelerates the progression of head and neck squamous cell carcinoma by targeting PD-L1 to activate PI3K/AKT signaling pathway.

Liu P, Kong X, Yi S, Chen Y, Luo W World J Surg Oncol. 2024; 22(1):34.

PMID: 38273364 PMC: 10809513. DOI: 10.1186/s12957-023-03274-5.

References

Wacher C, Muller M, Hofer M, Getts D, Zabaras R, Ousman S . Coordinated regulation and widespread cellular expression of interferon-stimulated genes (ISG) ISG-49, ISG-54, and ISG-56 in the central nervous system after infection with distinct viruses. J Virol. 2006; 81(2):860-71. PMC: 1797448. DOI: 10.1128/JVI.01167-06. View

Distler M, Ruckert F, Hunger M, Kersting S, Pilarsky C, Saeger H . Evaluation of survival in patients after pancreatic head resection for ductal adenocarcinoma. BMC Surg. 2013; 13:12. PMC: 3639824. DOI: 10.1186/1471-2482-13-12. View

Van Den Broeck A, Vankelecom H, van Eijsden R, Govaere O, Topal B . Molecular markers associated with outcome and metastasis in human pancreatic cancer. J Exp Clin Cancer Res. 2012; 31:68. PMC: 3511800. DOI: 10.1186/1756-9966-31-68. View

Fensterl V, White C, Yamashita M, Sen G . Novel characteristics of the function and induction of murine p56 family proteins. J Virol. 2008; 82(22):11045-53. PMC: 2573266. DOI: 10.1128/JVI.01593-08. View

Knosel T, Emde A, Schluns K, Chen Y, Jurchott K, Krause M . Immunoprofiles of 11 biomarkers using tissue microarrays identify prognostic subgroups in colorectal cancer. Neoplasia. 2005; 7(8):741-7. PMC: 1501883. DOI: 10.1593/neo.05178. View

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun M . Cancer statistics, 2009. CA Cancer J Clin. 2009; 59(4):225-49. DOI: 10.3322/caac.20006. View

Niess H, Camaj P, Mair R, Renner A, Zhao Y, Jackel C . Overexpression of IFN-induced protein with tetratricopeptide repeats 3 (IFIT3) in pancreatic cancer: cellular "pseudoinflammation" contributing to an aggressive phenotype. Oncotarget. 2015; 6(5):3306-18. PMC: 4413655. DOI: 10.18632/oncotarget.2494. View

Hertzog P, Forster S, Samarajiwa S . Systems biology of interferon responses. J Interferon Cytokine Res. 2011; 31(1):5-11. DOI: 10.1089/jir.2010.0126. View

Varadhachary G, Wolff R, Crane C, Sun C, Lee J, Pisters P . Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008; 26(21):3487-95. DOI: 10.1200/JCO.2007.15.8642. View

10.

Ferrone C, Pieretti-Vanmarcke R, Bloom J, Zheng H, Szymonifka J, Wargo J . Pancreatic ductal adenocarcinoma: long-term survival does not equal cure. Surgery. 2012; 152(3 Suppl 1):S43-9. PMC: 3806092. DOI: 10.1016/j.surg.2012.05.020. View

11.

Carmichael J . The role of gemcitabine in the treatment of other tumours. Br J Cancer. 1998; 78 Suppl 3:21-5. PMC: 2062798. DOI: 10.1038/bjc.1998.750. View

12.

MacMicking J . Interferon-inducible effector mechanisms in cell-autonomous immunity. Nat Rev Immunol. 2012; 12(5):367-82. PMC: 4150610. DOI: 10.1038/nri3210. View

13.

Chiorean E, Coveler A . Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapies. Drug Des Devel Ther. 2015; 9:3529-45. PMC: 4500614. DOI: 10.2147/DDDT.S60328. View

14.

Michael M, Moore M . Clinical experience with gemcitabine in pancreatic carcinoma. Oncology (Williston Park). 1997; 11(11):1615-22; discussion 1622, 1625-7. View

15.

Fensterl V, Sen G . The ISG56/IFIT1 gene family. J Interferon Cytokine Res. 2010; 31(1):71-8. PMC: 3021354. DOI: 10.1089/jir.2010.0101. View

16.

Dusch N, Weiss C, Strobel P, Kienle P, Post S, Niedergethmann M . Factors predicting long-term survival following pancreatic resection for ductal adenocarcinoma of the pancreas: 40 years of experience. J Gastrointest Surg. 2013; 18(4):674-81. DOI: 10.1007/s11605-013-2408-x. View

17.

Sadler A, Williams B . Interferon-inducible antiviral effectors. Nat Rev Immunol. 2008; 8(7):559-68. PMC: 2522268. DOI: 10.1038/nri2314. View

18.

Niess H, Camaj P, Renner A, Ischenko I, Zhao Y, Krebs S . Side population cells of pancreatic cancer show characteristics of cancer stem cells responsible for resistance and metastasis. Target Oncol. 2014; 10(2):215-27. DOI: 10.1007/s11523-014-0323-z. View

19.

Mayo S, Austin D, Sheppard B, Mori M, Shipley D, Billingsley K . Adjuvant therapy and survival after resection of pancreatic adenocarcinoma: a population-based analysis. Cancer. 2010; 116(12):2932-40. DOI: 10.1002/cncr.25082. View

20.

Polistina F, Di Natale G, Bonciarelli G, Ambrosino G, Frego M . Neoadjuvant strategies for pancreatic cancer. World J Gastroenterol. 2014; 20(28):9374-83. PMC: 4110569. DOI: 10.3748/wjg.v20.i28.9374. View